U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry RACEMIC
Molecular Formula C22H28N
Molecular Weight 306.4644
Optical Activity ( + / - )
Defined Stereocenters 0 / 2
E/Z Centers 0
Charge 1

SHOW SMILES / InChI
Structure of PRIFINIUM

SMILES

CC[N+]1(CC)CCC(C1C)=C(C2=CC=CC=C2)C3=CC=CC=C3

InChI

InChIKey=ZYEPZINLLPPBMI-UHFFFAOYSA-N
InChI=1S/C22H28N/c1-4-23(5-2)17-16-21(18(23)3)22(19-12-8-6-9-13-19)20-14-10-7-11-15-20/h6-15,18H,4-5,16-17H2,1-3H3/q+1

HIDE SMILES / InChI
Molecular Formula C22H28N
Molecular Weight 306.4644
Charge 1
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry MIXED
Additional Stereochemistry No
Defined Stereocenters 0 / 2
E/Z Centers 0
Optical Activity ( + / - )

Description

Prifinium bromide is antimuscarinic drug, which has antispasmodic, antiemetic effect. Prifinium bromideis approved for pain relief in Russia, Indonesia, Iraq, Tunisia and other countries.

CNS Activity

CNS Non-penetrant
1,040

Originator

Fujisawa Pharmaceutical
28

Approval Year

Unknown
149,124

Targets

Primary TargetPharmacologyConditionPotency
Muscarinic acetylcholine receptor
162
Antagonist
2,849

Conditions

ConditionModalityTargetsHighest PhaseProduct
Pain
619
 Primary
Approved
8,583
Reyabal
Gastric endoscopy
2
 Secondary
Approved
8,583
Reyabal
Vomiting
38
 Primary
Approved
8,583
Riabal

Cmax

ValueDoseCo-administeredAnalytePopulation
6.76 ng/mL
60 mg single, oral
 PRIFINIUM serum
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
2.13 h
7.5 mg single, intravenous
 PRIFINIUM serum
Homo sapiens
2.18 h
60 mg single, oral
 PRIFINIUM serum
Homo sapiens

Doses

PubMed

Patents

20040224012
20
20050096499
6
US4205074
2

Sample Use Guides

In Vivo Use Guide
Tablets of Reyabal, containing 325 mg Paracetamol and 30 mg Prifinium bromide, are indicated against pain 1-2 tablets a day.
Route of Administration: Oral
In Vitro Use Guide
Prifinium bromide depressed the amplitude of muscle contraction induced by electrical stimulation of the phrenic nerve at a concentration of 50 ug/ml, while large concentrations of 100 ug/ml produced no change on muscle contraction induced by direct stimulation of the muscle.
Substance Class Chemical
Record UNII
3C7TTK1K7K
Record Status Validated (UNII)
Record Version
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966